The disconnect between widespread medical cannabis adoption and rigorous scientific validation reveals a concerning gap in evidence-based medicine. While states increasingly authorize cannabis for medical conditions and healthcare systems embrace these policies, the underlying clinical foundation remains surprisingly thin. A comprehensive analysis of randomized controlled trials demonstrates that cannabis and cannabinoids lack robust evidence for most promoted therapeutic applications, challenging the rapid normalization of medical marijuana in clinical practice. The research examined multiple conditions where cannabis is commonly prescribed, finding insufficient data to support efficacy claims across the majority of approved indications. This evidence gap is particularly striking given the substance's Schedule I federal classification alongside its widespread state-level medical acceptance. The findings highlight specific limitations in study design, sample sizes, and duration that have prevented definitive conclusions about both benefits and potential harms. The clinical reality creates an unusual situation where physicians are recommending treatments with limited scientific backing, potentially exposing patients to unknown risks while delaying proven therapies. This research landscape becomes more complex when considering the entourage effect theories and variability in cannabis preparations, making standardized clinical assessment challenging. For health-conscious adults, these findings underscore the importance of approaching medical cannabis with appropriate skepticism despite regulatory approval. The gap between popular acceptance and scientific validation serves as a reminder that regulatory permission does not equal clinical proof, particularly for substances with complex pharmacological profiles and potential long-term consequences that remain poorly understood.